Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
FBRX
FBRX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
FBRX News
Forte Biosciences Receives Fast Track Designation for Celiac Disease
May 11 2026
Newsfilter
Forte Biosciences Prices Public Offering at $26.27 per Share
Apr 09 2026
seekingalpha
Forte Biosciences Prices Public Offering at $26.27 per Share
Apr 09 2026
Newsfilter
Forte Biosciences Launches Underwritten Public Offering
Apr 08 2026
seekingalpha
Forte Biosciences Reports FY 2025 Financial Results
Mar 31 2026
seekingalpha
Forte Biosciences Grants Equity Inducement Awards
Mar 17 2026
Newsfilter
GH Research (GHRS) Stock Surges 22.36% Ahead of Key Update
Jan 05 2026
NASDAQ.COM
Chardan Capital Reaffirms Buy Rating for Forte Biosciences with $61 Price Target
Nov 17 2025
Benzinga
Forte Biosciences, Inc. Announces Inducement Grants in Compliance with Nasdaq Listing Regulations
Oct 03 2025
Newsfilter
Forte Biosciences, Inc. to Present FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium
Sep 15 2025
Newsfilter
Forte Biosciences Prices $75 Mln Public Offering Of Common Stock And Pre-Funded Warrants
Jun 25 2025
NASDAQ.COM
Forte Biosciences Announces Pricing of $75 Million Public Offering
Jun 25 2025
Newsfilter
Forte Biosciences Announces Proposed Public Offering
Jun 24 2025
Newsfilter
Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!
Jun 23 2025
TipRanks
Forte Biosciences Stock (FBRX) Surges 25% on Positive Celiac Disease Trial Data
Jun 23 2025
TipRanks
Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study
Jun 23 2025
Newsfilter
Show More News
